Description
Cansalazine Pharmacodynamics
It has anti-inflammatory effect. It inhibits synthesis of arachidonic acid metabolites (prostaglandins), activity of neutrophil lipooxygenase, inhibits migration, degranulation and phagocytosis of neutrophils, secretion of immunoglobulins by lymphocytes; binds and destroys free oxygen radicals.
Indications
Treatment of exacerbations and prevention of relapses in ulcerative colitis and Crohn’s disease.
Contraindications .
Hypersensitivity to the components of the drug and other salicylic acid derivatives, blood diseases, peptic ulcer disease, glucose-6-phosphate dehydrogenase deficiency, hemorrhagic diathesis, severe renal/liver failure, children under 18 years old.
Dosage and administration
- Receiving the drug strictly as prescribed by your doctor.
- Adults. For treatment of acute condition of ulcerative colitis, orally 1 to 2 tablets 500 mg 3 times per day (daily dose 1.5 to 3.0 g of mesalazine), depending on the disease severity.
- In Crohn’s disease for treatment of exacerbation, depending on the disease severity, 1 to 3 tablets 500 mg 3 times a day (daily dose 1.5 to 4.5 g mesalazine).
- For relapse prevention in ulcerative colitis and Crohn’s disease the drug is prescribed 500 mg 3 times daily, if necessary for several years.
- The tablets should be taken as a whole, without chewing, in the morning, during the day and in the evening one hour before meals and with plenty of water. In distal forms of ulcerative colitis, simultaneous rectal administration of the drug in the form of suppositories or enemas, foams is preferable.
